Welcome to our dedicated page for Casi Pharmaceuticals news (Ticker: CASI), a resource for investors and traders seeking the latest updates and insights on Casi Pharmaceuticals stock.
CASI Pharmaceuticals Inc (CASI) is a biopharmaceutical innovator advancing therapies for oncology and immune-related disorders. This page provides investors and industry professionals with timely updates on clinical developments, regulatory milestones, and corporate announcements.
Key resources include: Press releases detailing product approvals, financial earnings reports, partnership agreements, and progress across the company’s pipeline. Track updates on therapies like EVOMELA® for multiple myeloma and CID-103 for immune-mediated conditions.
Bookmark this page to stay informed about CASI’s strategic initiatives in hematologic oncology and global commercialization efforts. Check regularly for verified updates directly from the company and trusted sources.
CASI Pharmaceuticals (NASDAQ: CASI) announced the filing of its annual report on Form 20-F for the fiscal year ending December 31, 2022, with the U.S. Securities and Exchange Commission on April 26, 2023. The report highlights the company's ongoing commitment to developing innovative therapeutics in hematology oncology and other unmet medical needs. Shareholders can request a free hard copy of the audited consolidated financial statements. The company aims to establish a strong presence in the Greater China market, leveraging its regulatory and commercial competencies alongside its global drug development expertise. More details are available on the company's investor relations website.
FAQ
What is the current stock price of Casi Pharmaceuticals (CASI)?
What is the market cap of Casi Pharmaceuticals (CASI)?
